跳至主要内容
临床试验/ACTRN12620000757910
ACTRN12620000757910招募中未知

Functional imaging-guided radiotherapy dose escalation in rectal adenocarcinoma: a feasibility study

Dr Myo Min0 个研究点目标入组 30 人开始时间: 2020年7月23日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Able to give informed consent
  • - Histologically-proven primary rectal adenocarcinoma within 0-10cm of anorectal junction on MRI or enteroscopy (T3, T4 or node positive disease with no evidence of metastatic spread (M0) on staging CT-chest/abdomen/pelvis (i.e. stage II/III disease))
  • - Patient undergoing curative intent neoadjuvant radiotherapy +/- chemotherapy
  • -- Neoadjuvant radiotherapy must be first component of neoadjuvant therapy (i.e. no induction course)
  • -- Concurrent chemotherapy can include capecitabine or fluorouracil

排除标准

  • - Contraindication to MRI studies (e.g. significant claustrophobia, incompatible pacemaker/implantable defibrillator, implanted metals)
  • - Patients receiving total neoadjuvant chemotherapy
  • - Significant imaging artefact precluding accurate MRI-guided radiotherapy planning (bilateral hip replacement etc.)
  • - Previous radiotherapy to pelvis
  • - Other malignancy conferring life expectancy of less than 3 years
  • - Pregnancy
  • - Active inflammatory bowel disease
  • - Prior diagnosis of connective tissue disorder

研究者

发起方
Dr Myo Min

相似试验